LY 2157299 - Galunisertib

Based on 589 reference(s) in Google Scholar 9 10 589

Axon 1491

CAS [700874-72-2]

MF C22H19N5O
MW 369.42

Purity: 99%
Soluble in 0.1N HCl(aq) and DMSO

LY 2157299

Description

Orally active transforming growth factor β receptor (TGF-βR) kinase inhibitor under clinical development; IC50 values to be 86 nm (TβR1) and 2 nM (TβR2) respectively.

L Bueno et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice. Eur. J. Cancer. 2008, 44(1), 142-150.

Z Liu et al. VEGF and inhibitors of TGFβ type-I receptor kinase synergistically promote blood-vessel formation by inducing 5-integrin expression. J. Cell Sci. 2009, 122, 3294-3302.

P Workman. New cancer drugs in the horizon. Fut. Oncology 2005, 1(3), 315-318.

D. Muñoz-Espín et al. Programmed cell senescence during mammalian embryonic development. Cell. 2013 Nov 21;155(5):1104-18.

List of publications using LY 2157299 (Axon 1491) purchased from Axon Medchem

Apoptosis Cell Signaling & Oncology Stem Cell TGF-β RSTK class II; EC 2.7.11.30 TGF-βR

TGF-βR2 inhibitor

Chemical name

4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoline-6-carboxylic acid amide

Parent CAS No.

[700874-72-2]

产品资料